M
Mahmoud Shehata
Researcher at University of Cincinnati
Publications - 39
Citations - 1448
Mahmoud Shehata is an academic researcher from University of Cincinnati. The author has contributed to research in topics: Virus & Middle East respiratory syndrome coronavirus. The author has an hindex of 14, co-authored 31 publications receiving 1075 citations.
Papers
More filters
Journal ArticleDOI
Seroepidemiology for MERS coronavirus using microneutralisation and pseudoparticle virus neutralisation assays reveal a high prevalence of antibody in dromedary camels in Egypt, June 2013
Ranawaka A.P.M. Perera,Peigang Wang,Peigang Wang,Mokhtar R. Gomaa,Rabeh El-Shesheny,Ahmed Kandeil,Ola Bagato,Lewis Y. Siu,Mahmoud Shehata,Ahmed S. Kayed,Yassmin Moatasim,Ming Yuan Li,Leo L.M. Poon,Yi Guan,Richard J. Webby,Mohamed A. Ali,J. S. Peiris,Ghazi Kayali +17 more
TL;DR: The newly developed ppNT assay does not require Biosafety Level 3 containment and is thus a relatively high-throughput assay, well suited for large-scale seroepidemiology studies which are needed to better understand the ecology and epidemiology of MERS-CoV.
Journal ArticleDOI
MERS Coronaviruses in Dromedary Camels, Egypt
Daniel K.W. Chu,Leo L.M. Poon,Mokhtar Gomaa,Mahmoud Shehata,Ranawaka A.P.M. Perera,Dina Abu Zeid,Amira S. El Rifay,Lewis Y. Siu,Yi Guan,Richard J. Webby,Mohamed A. Ali,Malik Peiris,Ghazi Kayali +12 more
TL;DR: The near-full-genome sequence of Middle East respiratory syndrome coronavirus (MERS-CoV) is identified from a nasal swab specimen from a dromedary camel in Egypt and it is found that viruses genetically very similar to human MERS- coV are infecting dromingaries beyond the Arabian Peninsula.
Journal ArticleDOI
FDA-Approved Drugs with Potent In Vitro Antiviral Activity against Severe Acute Respiratory Syndrome Coronavirus 2.
Ahmed Mostafa,Ahmed Kandeil,Yaseen A.M.M. Elshaier,Omnia Kutkat,Yassmin Moatasim,Adel A. Rashad,Mahmoud Shehata,Mokhtar R. Gomaa,Noura Mahrous,Sara H. Mahmoud,Mohamed GabAllah,Hisham A. Abbas,Ahmed El Taweel,Ahmed E. Kayed,Mina Nabil Kamel,Mohamed El Sayes,Dina B. Mahmoud,Rabeh El-Shesheny,Ghazi Kayali,Mohamed A. Ali +19 more
TL;DR: It is shown that Azithromycin can selectively impair SARS-CoV-2 replication, but not the Middle East Respiratory Syndrome Coronavirus (MERS- coV), and the results suggest that Piroxicam should be prescribed in combination with Azathromycin for COVID-19 patients.
Journal ArticleDOI
Active Surveillance for Avian Influenza Virus, Egypt, 2010-2012
Ghazi Kayali,Ahmed Kandeil,Rabeh El-Shesheny,Ahmed S. Kayed,Mokhtar Gomaa,Asmaa M. Maatouq,Mahmoud Shehata,Yassmin Moatasim,Ola Bagato,Zhipeng Cai,Adam Rubrum,M. A. Kutkat,Pamela McKenzie,Robert G. Webster,Richard J. Webby,Mohamed A. Ali +15 more
TL;DR: Genetic and antigenic analyses of viruses revealed that influenza A(H5N1) clade 2.2.1 viruses are dominant and that all subtype H9N2 viruses are G1-like, which poses concern for potential reassortment.
Journal ArticleDOI
Systematic, active surveillance for Middle East respiratory syndrome coronavirus in camels in Egypt
Mohamed A. Ali,Mahmoud Shehata,Mokhtar R. Gomaa,Ahmed Kandeil,Rabeh El-Shesheny,Ahmed S. Kayed,Ahmed Nageh El-Taweel,Mohamed Atea,Nagla Hassan,Ola Bagato,Yassmin Moatasim,Sara H. Mahmoud,Omnia Kutkat,Asmaa M. Maatouq,Ahmed Osman,Pamela McKenzie,Richard J. Webby,Ghazi Kayali +17 more
TL;DR: The hypothesis that camels are a reservoir for MERS-CoV and that camel trade is an important route of introducing the virus into importing countries is supported and findings related to waning antibodies and re-infection have implications for camel vaccine development, disease management and zoonotic threat.